Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension (2022)
https://pubmed.ncbi.nlm.nih.gov/34196498/

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (2020)
https://pubmed.ncbi.nlm.nih.gov/31813637/

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2020)
https://pubmed.ncbi.nlm.nih.gov/31685553/

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2020)
https://pubmed.ncbi.nlm.nih.gov/31685553/

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2020)
https://pubmed.ncbi.nlm.nih.gov/31685553/

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31551538/

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial (2019)
https://pubmed.ncbi.nlm.nih.gov31732180/

Axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28110981/